Yao, Wantong
Rose, Johnathon L.
Wang, Wei
Seth, Sahil
Jiang, Hong
Taguchi, Ayumu
Liu, Jintan
Yan, Liang
Kapoor, Avnish
Hou, Pingping
Chen, Ziheng
Wang, Qiuyun
Nezi, Luigi
Xu, Zhaohui
Yao, Jun
Hu, Baoli
Pettazzoni, Piergiorgio F.
Ho, I Lin
Feng, Ningping
Ramamoorthy, Vandhana
Jiang, Shan
Deng, Pingna
Ma, Grace J.
Den, Peter
Tan, Zhi
Zhang, Shu Xing
Wang, Huamin
Wang, Y. Alan
Deem, Angela K.
Fleming, Jason B.
Carugo, Alessandro
Heffernan, Timothy P.
Maitra, Anirban
Viale, Andrea
Ying, Haoqiang
Hanash, Samir
DePinho, Ronald A.
Draetta, Giulio F.
Article History
Received: 27 February 2018
Accepted: 8 February 2019
First Online: 27 March 2019
Competing interests
: R.A.D. is a co-founder, advisor and director of Tvardi Therapeutics. G.F.D. reports personal fees from and stock ownership in Karyopharm Therapeutics, Forma Therapeutics, Metabomed, BiovelocITA, Nurix and Orionis Biosciences; and personal fees from Blueprint Medicines, Taiho Pharmaceutical, Symphogen and Helsinn Ventures.